| 17.46 0.09 (0.52%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.81  |
1-year : | 24.31 |
| Resists | First : | 17.81 |
Second : | 20.81 |
| Pivot price | 16.38 |
|||
| Supports | First : | 16.31 |
Second : | 15.39 |
| MAs | MA(5) : | 17.13 |
MA(20) : | 16.26 |
| MA(100) : | 17.5 |
MA(250) : | 20.41  |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 80.9 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 33.61 | Low : | 15.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INMD ] has closed below upper band by 12.4%. Bollinger Bands are 52.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.82 - 17.88 | 17.88 - 17.94 |
| Low: | 17 - 17.08 | 17.08 - 17.15 |
| Close: | 17.33 - 17.44 | 17.44 - 17.55 |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Mon, 16 Sep 2024
Federated Hermes Inc. Has $20.52 Million Stock Holdings in InMode Ltd. (NASDAQ:INMD) - MarketBeat
Sat, 14 Sep 2024
InMode Ltd. (NASDAQ:INMD) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
Tue, 10 Sep 2024
InMode Announces Share Repurchase Program of Up to 7.68 Million Shares - StockTitan
Tue, 10 Sep 2024
InMode Announces Share Repurchase Program of Up to 7.68 Million Shares - PR Newswire
Wed, 14 Aug 2024
InMode Ltd. (INMD): Challenges and Insights in the Beauty Industry - Yahoo Finance
Mon, 12 Aug 2024
InMode: Still Undervalued, But Short-Term Risks Warrant Caution (Rating Downgrade) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 76 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 6,050 (K) |
| Shares Short P.Month | 6,970 (K) |
| EPS | 1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.94 |
| Profit Margin | 35.8 % |
| Operating Margin | 21.1 % |
| Return on Assets (ttm) | 10.5 % |
| Return on Equity (ttm) | 21 % |
| Qtrly Rev. Growth | -36.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.46 |
| EBITDA (p.s.) | 1.76 |
| Qtrly Earnings Growth | -57 % |
| Operating Cash Flow | 169 (M) |
| Levered Free Cash Flow | 119 (M) |
| PE Ratio | 10.09 |
| PEG Ratio | -9.8 |
| Price to Book value | 1.95 |
| Price to Sales | 3.19 |
| Price to Cash Flow | 7.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|